Advertisment

Inavolisib Shows Promising Results in Advanced Breast Cancer Treatment: Insights from INAVO120 Trial

author-image
Anthony Raphael
New Update
NULL

Inavolisib Shows Promising Results in Advanced Breast Cancer Treatment: Insights from INAVO120 Trial

Advertisment

Recent medical advancements have brought new hope to patients with recurrent PIK3CA-mutated HR-positive, HER2-negative advanced breast cancer. The INAVO120 trial has revealed that the addition of inavolisib to the existing treatment regimen of palbociclib (Ibrance) and fulvestrant (Faslodex) can significantly improve patient outcomes.

Advertisment

Promising Results from the INAVO120 Trial

The INAVO120 trial demonstrated impressive results with the addition of inavolisib to the standard treatment. Data showed more than a doubling of median progression-free survival (PFS) from 7.3 months to 15 months. This encouraging outcome suggests a trend toward improved overall survival (OS), potentially marking the triplet therapy as a new standard of care for these patients.

Safety Profile of the Triplet Therapy

Advertisment

The combination of inavolisib, palbociclib, and fulvestrant demonstrated a manageable safety profile. No new safety signals were reported during the trial. However, patients should be aware of potential side effects, including hyperglycemia, diarrhea, rash, stomatitis, and ocular toxicity associated with inavolisib.

Favorable Outcomes and Follow-up Trials

Notably, the trial recorded a 57% reduction in the risk of progression or death compared with the doublet therapy. Furthermore, the confirmed objective response rates were significantly higher in the inavolisib arm. The promising results have led to consideration of inavolisib as a potential treatment option for patients with advanced breast cancer. Ongoing trials are expected to provide further insight into the application and effectiveness of inavolisib.

Advertisment

INAVO120 Trial: A Closer Look

The INAVO120 trial studied a total of 325 patients who were randomly assigned to either the investigational or control treatment arm. The primary endpoint was PFS, while secondary endpoints included overall survival (OS), objective response rate, and clinical benefit rate. With OS data still immature, further trials are needed for comprehensive evaluation.

Exploring New Frontiers in Breast Cancer Treatment

Advertisment

Genentech, the creator of inavolisib, continues to investigate its potential in combination with palbociclib and fulvestrant for the treatment of breast cancer. The INAVO120 study, funded by F. Hoffmann-La Roche Ltd., is part of three phase 3 clinical studies exploring the use of inavolisib in PIK3CA-mutated metastatic breast cancer. The positive outcomes from this trial represent a significant stride towards improving breast cancer treatment and patient survival rates.

Conclusion

The promising results from the INAVO120 trial have opened new avenues in the treatment of advanced breast cancer. While further trials are required, the use of inavolisib in combination with palbociclib and fulvestrant could soon become a standard therapy for patients with recurrent PIK3CA-mutated HR-positive, HER2-negative advanced breast cancer.

Advertisment
Chat with Dr. Medriva !